New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

    NEXT STORY
    Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference
    PREV STORY
    Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe

    author_avatar
    NASDAQ Market News

    XBiotech to Provide First Quarter 2017 Business Update

    AUSTIN, Texas, April 28, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today it ...

    author_avatar
    NASDAQ Market News

    Five Prime Therapeutics Provides Update on FP-1039 Clinical Program

    SOUTH SAN FRANCISCO, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...

    author_avatar
    NASDAQ Market News